BOSTON – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today. Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “We’re very pleased with today’s affirmative shareholder vote, which...
Latest News
CHESHIRE, Conn. & PARIS — Alexion Pharma France and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today received the 2009 Prix Galien France for Soliris(R) (eculizumab) in the category of medicines for rare diseases. The award recognizes the scientific innovation represented by the complement-inhibition technology of Soliris, and the impact the drug...
VANCOUVER, Canada — Algernon Pharmaceuticals Inc. a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF). The Company was previously granted...
ATLANTA, GA — Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety...
INDIANAPOLIS — Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA(R) (pemetrexed for injection) as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development for...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment...